Combining CHK1 Inhibitor with Nano Medicine Technology to Reduce Toxicity in Solid Tumor Targeting
Time: 4:30 pm
day: Day One
Details:
- Discussing how CHK1 inhibitors target the DNA damage response by preventing cell cycle arrest and DNA repair in cancer cells, leading to apoptosis under conditions of high replication stress
- Exploring the role of liposomal encapsulation in modifying the pharmacokinetics of CHK1 inhibitors, such as SMP-3124, to enhance anti-tumor activity and reduce systemic toxicity
- Assessing the potential benefits of this combination approach in improving the therapeutic index of CHK1 inhibitors in solid tumor treatments, focusing on reducing side effects and improving patient outcomes
